Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Irritable Bowel Syndrome With Constipation Clear all
Completed Phase 2 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT01722318
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
99
States / cities
Birmingham, Alabama • Dothan, Alabama • Glendale, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated May 27, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Withdrawn No phase listed Observational

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS

NCT04214470
View directory record Official record
Conditions
Irritable Bowel, Irritable Bowel Syndrome, Irritable Bowel Syndrome With Diarrhea, Irritable Bowel Syndrome Mixed, Irritable Bowel Syndrome With Constipation, Irritable Bowel Syndrome Without Diarrhea, Irritable Bowel Syndrome Aggravated, Irritable Bowel Syndrome Characterized by Constipation, Irritable Bowel Syndrome Characterised by Alternating Bowel Habit
Interventions
No intervention
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT02559206
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Matching Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
71
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2020 · Synced Jul 22, 2026, 5:59 AM EDT
Not yet recruiting Not applicable Interventional

Trans Auricular Vagal Nerve Stimulation in Patients With IBS-C

NCT07662083
View directory record Official record
Conditions
Irritable Bowel Syndrome (IBS-C)
Interventions
Transcutaneous Auricular Vagus Nerve Stimulation (ta-VNS), Sham Transcutaneous Auricular Vagus Nerve Stimulation
Device
Lead sponsor
West Virginia University
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional

SAT vs Escitalopram for Rectal Hypersensitivity

NCT00584571
View directory record Official record
Conditions
Rectal Hypersensitivity, Irritable Bowel Syndrome-Constipation
Interventions
Sensory Adaptation Training, Escitalopram Therapy
Procedure · Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2019
U.S. locations
2
States / cities
Augusta, Georgia • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Biomarkers for Intestinal Permeability in Patients With Constipation

NCT02246647
View directory record Official record
Conditions
Intestinal Diseases, Irritable Bowel Syndrome, Constipation
Interventions
Permeability measurement, Esophagogastroduodenoscopy, Flexible sigmoidoscopy
Diagnostic Test · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years · Female only
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 1 Interventional

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

NCT04655599
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Olorinab, Placebo
Drug
Lead sponsor
Arena Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced Jul 22, 2026, 5:59 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

NCT05643534
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
12 Years to 17 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
39
States / cities
Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 2 Interventional Results available

A Study of the Effect of SYN-010 on Subjects With IBS-C

NCT02495623
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
SYN-010 21 mg, SYN-010 42 mg, Placebo
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2018 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional

Effect of Tenapanor on the Metagenomics and Metabolomics of Patients With Irritable Bowel Syndrome With Constipation

NCT05995899
View directory record Official record
Conditions
IBS, IBS - Irritable Bowel Syndrome
Interventions
Tenapanor
Drug
Lead sponsor
Kyle Staller, MD, MPH
Other
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Recruiting Phase 2Phase 3 Interventional

Home Transcutaneous Electrical Acustimulation (TEA)

NCT05519683
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
TEA, Lexapro
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 13, 2025 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A 12-Week Study With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Tenapanor for the Treatment of IBS-C

NCT02621892
View directory record Official record
Conditions
Constipation Predominant Irritable Bowel Syndrome
Interventions
Tenapanor, Placebo
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
18 Years to 75 Years
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
111
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2020 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation

NCT00948818
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide 290 micrograms, Matching placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
803 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
111
States / cities
Birmingham, Alabama • Hueytown, Alabama • Huntsville, Alabama + 94 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Jul 22, 2026, 5:59 AM EDT
Enrolling by invitation Phase 3 Interventional

Safety Study of Tenapanor for the Treatment of Pediatric Patients (6 to Less Than 18 Years Old) With IBS-C

NCT05905926
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions
Tenapanor
Drug
Lead sponsor
Ardelyx
Industry
Eligibility
6 Years to 18 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
27
States / cities
Foley, Alabama • Anaheim, California • Doral, Florida + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation

NCT03054506
View directory record Official record
Conditions
Constipation, Chronic Idiopathic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
CSP01, Carboxymethylcellulose (CMC), Placebo
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
22 Years to 70 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 3 Interventional

Long-Term Safety of Renzapride in Women With Constipation-Predominant Irritable Bowel Syndrome (IBS-C)

NCT00607971
View directory record Official record
Conditions
Constipation-Predominant Irritable Bowel Syndrome
Interventions
Renzapride
Drug
Lead sponsor
Alizyme
Industry
Eligibility
18 Years and older · Female only
Enrollment
939 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
126
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 112 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2008 · Synced Jul 22, 2026, 5:59 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation

NCT02559817
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide Dose A, Linaclotide Dose B, Linaclotide Dose C, Linaclotide Approved Adult Dose, Matching Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
7 Years to 17 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
46
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • Anaheim, California + 39 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2020 · Synced Jul 22, 2026, 5:59 AM EDT
Completed No phase listed Observational

Cohort Study of Bowel Function Following Robotic-assisted Laparoscopic Sacrocolpopexy

NCT01618292
View directory record Official record
Conditions
Pelvic Organ Prolapse, Constipation, Bowel Dysfunction, Irritable Bowel Syndrome
Interventions
Robotic sacral colpopexy
Procedure
Lead sponsor
Atlantic Health System
Other
Eligibility
Female only
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Morristown, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 27, 2014 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)

NCT01085643
View directory record Official record
Conditions
Constipation-predominant Irritable Bowel Syndrome
Interventions
Lubiprostone, Placebo
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2011 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Not applicable Interventional Results available

Effect of Tai Chi as Treatment for IBS-C

NCT04132804
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation
Interventions
Tai Chi
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 4 Interventional Results available

An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation

NCT02590432
View directory record Official record
Conditions
Irritable Bowel Syndrome With Constipation, Chronic Idiopathic Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
79
States / cities
Anniston, Alabama • Athens, Alabama • Childersburg, Alabama + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)

NCT04026113
View directory record Official record
Conditions
Functional Constipation, Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
6 Years to 17 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
79
States / cities
Birmingham, Alabama • Foley, Alabama • Saraland, Alabama + 62 more
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

NCT02387359
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Plecanatide, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,054 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
155
States / cities
Athens, Alabama • Birmingham, Alabama • Dothan, Alabama + 142 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jul 22, 2026, 5:59 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

NCT03573908
View directory record Official record
Conditions
Irritable Bowel Syndrome Characterized by Constipation
Interventions
Linaclotide, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
79
States / cities
Huntsville, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Jul 22, 2026, 5:59 AM EDT